Bayesian Approach to Personalized Benefit-Risk Assessment

References

• Blackwell, D., and MacQueen, J. B. (1973), “Ferguson Distributions via Pólya Urn Schemes,” The Annals of Statistics, 1, 353–355.
   Google Scholar
• Brown, E. R., and Ibrahim, J. G. (2003), “Bayesian Approaches to Joint Cure-Rate and Longitudinal Models With Applications to Cancer Vaccine Trials,” Biometrics, 59, 686–693.
   Google Scholar
• Califf, R. M. (2007), “Benefit Assessment of Therapeutic Products: The Centers for Education and Research on Therapeutics,” Pharmacoepidemiology and Drug Safety, 16, 5–16.
   Google Scholar
• Chen, M.-H., Shao, Q.-M., and Ibrahim, J. G. (2000), Monte Carlo Methods in Bayesian Computation (Springer Series in Statistics), New York: Springer.
   Google Scholar
• Chib, S. (1993), “Bayes Regression With Autoregressive Errors: A Gibbs Sampling Approach,” Journal of Econometrics, 58, 275–294.
   Google Scholar
• Chib, S., and Greenberg, E. (1994), “Bayes Inference in Regression Models With Arma(p, q) Errors,” Journal of Econometrics, 64, 183–206.
   Google Scholar
• Chib, S., Greenberg, E., and Winkelmann, R. (1998), “Posterior Simulation and Bayes Factors in Panel Count Data Models,” Journal of Econometrics, 86, 33–54.
   Google Scholar
• Chuang-Stein, C. (1994), “A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials,” Controlled Clinical Trials, 15, 30–43.
   Google Scholar
• Chuang-Stein, C., Entsuah, R., and Pritchett, Y. (2008), “Measures for Conducting Comparative Benefit: Risk Assessment,” Drug Information Journal, 42, 223–233.
   Google Scholar
• Chuang-Stein, C., Mohberg, N. R., and Sinkula, M. S. (1991), “Three Measures for Simultaneously Evaluating Benefits and Risks Using Categorical Data From Clinical Trials,” Statistics in Medicine, 10, 1349–1359.
   Google Scholar
• Escobar, M. D., and West, M. (1995), “Bayesian Density Estimation and Inference Using Mixtures,” Journal of the American Statistical Association, 90, 577–588.
   Google Scholar
• European Medicines Agency (2011), Benefit-Risk Methodology Project: Work Package 3 Report: Field Tests. Available at www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp
   Google Scholar
• Ferguson, T. S. (1973), “A Bayesian Analysis of Some Nonparametric Problems,” The Annals of Statistics, 1, 209–230.
   Google Scholar
• Gamerman, D., and Lopes, H. F. (2006), Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference (Vol. 68), Boca Raton, FL: Chapman & Hall.
   Google Scholar
• Garrison, L. P., Towse, A., and Bresnahan, B. W. (2007), “Assessing a Structured, Quantitative Health Outcomes Approach to Drug Risk-Benefit Analysis,” Health Affairs, 26, 684–695.
   Google Scholar
• Geisser, S. (1980), Discussion of “Sampling and Bayes’ Inference in Scientific Modeling and Robustness” by George E.P. Box, Journal of the Royal Statistical Society, Series A, 143, 416–417.
   Google Scholar
• Gelber, R. D., Gelman, R. S., and Goldhirsch, A. (1989), “A Quality-of-Life-Oriented Endpoint for Comparing Therapies,” Biometrics, 3, 781–795.
   Google Scholar
• Gelfand, A. E., Dey, D. K., and Chang, H. (1992), “Model Determination Using Predictive Distributions With Implementation via Sampling-Based Methods,” Bayesian Statistics, 4, 147–159.
   Google Scholar
• Ghosh, P., Basu, S., and Tiwari, R. C. (2009), “Bayesian Analysis of Cancer Rates From SEER Program Using Parametric and Semiparametric Joinpoint Regression Models,” Journal of the American Statistical Association, 104, 439–452.
   Google Scholar
• Glasziou, P., Simes, R., and Gelber, R. (1990), “Quality Adjusted Survival Analysis,” Statistics in Medicine, 9, 1259–1276.
   Google Scholar
• Guha, S. (2008), “Posterior Simulation in the Generalized Linear Mixed Model With Semiparametric Random Effects,” Journal of Computational and Graphical Statistics, 17, 410–425.
   Google Scholar
• Guo, J. J., Pandey, S., Doyle, J., Bian, B., Lis, Y., and Raisch, D. W. (2010), “A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy-Report of The Ispor Risk–Benefit Management Working Group,” Value in Health, 13, 657–666.
   Google Scholar
• Ho, M.-W., Tu, W., Ghosh, P., and Tiwari, R. C. (2013), “A Nested Dirichlet Process Analysis of Cluster Randomized Trial Data With Application in Geriatric Care Assessment,” Journal of the American Statistical Association, 108, 48–68.
   Google Scholar
• Holden, W. L., Juhaeri, J., and Dai, W. (2003a), “Benefit-Risk Analysis: A Proposal Using Quantitative Methods,” Pharmacoepidemiology and Drug Safety, 12, 611–616.
   Google Scholar
• ——— (2003b), “Benefit-Risk Analysis: Examples Using Quantitative Methods,” Pharmacoepidemiology and Drug Safety, 12, 693–697.
   Google Scholar
• Ibrahim, J. G., and Chen, M.-H. (2000), “Power Prior Distributions for Regression Models,” Statistical Science, 15, 46–60.
   Google Scholar
• McCullagh, P., and Nelder, J. A. (1989), Generalized Linear Models, Boca Raton, FL: Chapman & Hall/CRC.
   Google Scholar
• Neal, R. M. (2000), “Markov Chain Sampling Methods for Dirichlet Process Mixture Models,” Journal of Computational and Graphical Statistics, 9, 249–265.
   Google Scholar
• Norton, J. D. (2011), “A Longitudinal Model and Graphic for Benefit-Risk Analysis, With Case Study,” Drug Information Journal, 45, 741–747.
   Google Scholar
• Payne, J. T., and Loken, M. (1975), “A Survey of the Benefits and Risks in the Practice of Radiology,” CRC Critical Reviews in Clinical Radiology and Nuclear Medicine, 6, 425–439.
   Google Scholar
• Ponce, R. A., Bartell, S. M., Wong, E. Y., LaFlamme, D., Carrington, C., Lee, R. C., Patrick, D. L., Faustman, E. M., and Bolger, M. (2000), “Use of Quality-Adjusted Life Year Weights With Dose-Response Models for Public Health Decisions: A Case Study of the Risks and Benefits of Fish Consumption,” Risk Analysis, 20, 529–542.
   Google Scholar
• Sethuraman, J. (1994), “A Constructive Definition of Dirichlet Priors,” Statistica Sinica, 4, 639–650.
   Google Scholar
• Sethuraman, J., and Tiwari, R. C. (1982), “Convergence of Dirichlet Measures and the Interpretation of Their Parameter,” Statistical Decision Theory and Related Topics III, 2, 305–315.
   Google Scholar
• Shahbaba, B., and Neal, R. (2009), “Nonlinear Models Using Dirichlet Process Mixtures,” The Journal of Machine Learning Research, 10, 1829–1850.
   Google Scholar
• Shakespeare, T. P., Gebski, V. J., Veness, M. J., and Simes, J. (2001), “Improving Interpretation of Clinical Studies by Use of Confidence Levels, Clinical Significance Curves, and Risk-Benefit Contours,” The Lancet, 357, 1349–1353.
   Google Scholar
• Spiegelhalter, D. J., Best, N. G., Carlin, B. P., and Van Der Linde, A. (2002), “Bayesian Measures of Model Complexity and Fit,” Journal of the Royal Statistical Society, Series B, 64, 583–639.
   Google Scholar
• Wen, S., Zhang, L., and Yang, B. (2014), “Two Approaches to Incorporate Clinical Data Uncertainty Into Multiple Criteria Decision Analysis for Benefit-Risk Assessment of Medicinal Products,” Value in Health, 17, 619–628.
   Google Scholar
• Zeger, S. L., and Karim, M. R. (1991), “Generalized Linear Models With Random Effects; A Gibbs Sampling Approach,” Journal of the American Statistical Association, 86, 79–86.
   Google Scholar
• Zhao, Y., Zalkikar, J., Tiwari, R. C., and LaVange, L. M. (2014), “Bayesian Approach for Benefit-Risk Assessment,” Statistics in Biopharmaceutical Research, 6, 326–337.
   Google Scholar